The Hematological Malignancies Drugs Market Size is estimated to grow at a CAGR of 14.2% during the forecast period for 2024-2031.
Hematologic malignancies are cancers that most often start in the bone marrow or the immune system cells. Lymphom, leukemia, and multiple myeloma are the three most common blood malignancies. The development of innovative agents has contributed to improved outcomes for cancer patients in recent years, resulting in significant advancement in the field of cancer therapy. The COVID19 pandemic, on the other hand, has hampered current cancer patient treatments. Because of their immunosuppression, patients with haematological malignancies appear to be extremely prone to Covid-19 infection.
The multiple factors driving the growth of the Hematological Malignancies Drugs Market include the rising hematological malignancy cases, technological advances in therapy techniques, favourable regulatory environment, growing government funding for the R&D of innovative cancer therapies, spreading public awareness regarding the benefits of advanced blood cancer therapeutics, and the high demand for cost-efficient malignancy treatments. The increasing incidences of leukemia, lymphoma, and multiple myeloma cases led to the emergence of advanced therapeutics. For instance, in October 2021, Novartis acquired the US FDA approval for Scemblix (asciminib) to treat chronic myeloid leukemia (CML). Also, Bristol Myers Squibb (US) received U.S. FDA approval for Istodax (romidepsin), a histone deacetylase (HDAC) inhibitor, as monotherapy for the treatment of peripheral T-cell lymphoma (PTCL) in adult patients who have received at least one prior therapy. Thus, R&D activities are expected to offer new growth opportunities for the Hematological Malignancies Drugs Market in the forthcoming years.
However, the high cost of therapies, complex manufacturing methods, and the side effects of emerging therapies may inhibit market augmentation over the forecast years.
The Hematological Malignancies Drugs Market is classified based on drugs, pipeline products, indications, and region. By drugs, the market is segmented into monoclonal antibodies (Blincyto (Blinatumomab), Besponsa (Inotuzumab Ozogamicin), Lumoxiti (Moxetumomab Pasudotox), Mylotarg (Gemtuzumab Ozogamicin), Opdivo (Nivolumab), AiRuiKa (Camrelizumab), Tyvyt (Sintilimab), Tislelizumab, Gazyva (Obinutuzumab), Zynlonta (Loncastuximab Tesirine-lpyl), Darzalex (Daratumumab), Blenrep (Belantamab Mafodotin-blmf), Keytruda (Pembrolizumab), Adcetris (Brentuximab Vedotin), Arzerra (Ofatumumab)) and CAR-T cell therapy (Tecartus (Brexucabtagene Autoleucel), Kymriah (Tisagenlecleucel), Yescarta (Axicabtagene Ciloleucel), Breyanzi (Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel)). By pipeline products, the market is grouped into monoclonal antibodies (Teclistamab, Iomab-B, Ublituximab, CS1001) and CAR-T cell therapy (Ciltacabtagene Autoleucel (JNJ-68284528)). The indications segment comprises leukemia (acute lymphoblastic leukemia, chronic lymphoblastic leukemia, acute myeloid leukemia), lymphoma (Hodgkin’s lymphoma and Non-Hodgkin’s lymphoma), and multiple myeloma. Region-wise, the market is studied across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
North America dominated the Hematological Malignancies Drugs Market in 2023 and is expected to continue its trend over the forecast period (2024-2031) due to the surging R&D funding for malignancy therapeutics and the growing incidences of leukemia and lymphoma in this region.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD XX Billion |
|
Revenue Forecast In 2031 |
USD XX Billion |
|
Growth Rate CAGR |
CAGR of 14.20% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Billion and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Drugs, By Pipeline Products, By Indication |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc, Immune-Onc Therapeutics, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, and others. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Hematological Malignancies Drugs Market Snapshot
Chapter 4. Global Hematological Malignancies Drugs Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Clinical Trial/Pipeline Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Route of Administration, Estimates & Trend Analysis
5.1. By Drugs, & Market Share, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Drugs:
5.2.1. Monoclonal Antibodies
5.2.1.1. Blincyto (Blinatumomab)
5.2.1.2. Besponsa (Inotuzumab Ozogamicin)
5.2.1.3. Lumoxiti (Moxetumomab Pasudotox)
5.2.1.4. Mylotarg (Gemtuzumab Ozogamicin)
5.2.1.5. Opdivo (Nivolumab)
5.2.1.6. AiRuiKa (Camrelizumab)
5.2.1.7. Tyvyt (Sintilimab)
5.2.1.8. Tislelizumab
5.2.1.9. Gazyva (Obinutuzumab)
5.2.1.10. Zynlonta (Loncastuximab Tesirine-lpyl)
5.2.1.11. Darzalex (Daratumumab)
5.2.1.12. Blenrep (Belantamab Mafodotin-blmf)
5.2.1.13. Keytruda (Pembrolizumab)
5.2.1.14. Adcetris (Brentuximab Vedotin)
5.2.1.15. Arzerra (Ofatumumab)
5.2.2. CAR-T Cell Therapy
5.2.2.1. Tecartus (Brexucabtagene Autoleucel)
5.2.2.2. Kymriah (Tisagenlecleucel)
5.2.2.3. Yescarta (Axicabtagene Ciloleucel)
5.2.2.4. Breyanzi (Lisocabtagene Maraleucel)
5.2.2.5. Abecma (Idecabtagene Vicleucel)
Chapter 6. Market Segmentation 2: By Indications Estimates & Trend Analysis
6.1. By Pipeline Products & Market Share, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Pipeline Products:
6.2.1. Monoclonal Antibodies
6.2.1.1. Teclistamab
6.2.1.2. Iomab-B
6.2.1.3. Ublituximab
6.2.1.4. CS1001
6.2.2. CAR-T Cell Therapy
6.2.2.1. Ciltacabtagene Autoleucel (JNJ-68284528)
Chapter 7. Market Segmentation 3: By Pipeline Products Estimates & Trend Analysis
7.1. By Indications & Market Share, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Indications:
7.2.1. Leukemia
7.2.1.1. Acute Lymphoblastic Leukemia
7.2.1.2. Chronic Lymphoblastic Leukemia
7.2.1.3. Acute Myeloid Leukemia
7.2.2. Lymphoma
7.2.2.1. Hodgkin’s Lymphoma
7.2.2.2. Non-Hodgkin’s Lymphoma
7.2.3. Multiple Myeloma
Chapter 8. Hematological Malignancies Drugs Market Segmentation 5: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Hematological Malignancies Drugs Market revenue (US$ Million) estimates and forecasts By Drugs, 2024-2031
8.1.2. North America Hematological Malignancies Drugs Market revenue (US$ Million) estimates and forecasts By Pipeline Products, 2024-2031
8.1.3. North America Hematological Malignancies Drugs Market revenue (US$ Million) estimates and forecasts By Indications, 2024-2031
8.1.4. North America Hematological Malignancies Drugs Market revenue (US$ Million) estimates and forecasts by country, 2024-2031
8.2. Europe
8.2.1. Europe Hematological Malignancies Drugs Market revenue (US$ Million) By Drugs, 2024-2031
8.2.2. Europe Hematological Malignancies Drugs Market revenue (US$ Million) By Pipeline Products, 2024-2031
8.2.3. Europe Hematological Malignancies Drugs Market revenue (US$ Million) By Indications, 2024-2031
8.2.4. Europe Hematological Malignancies Drugs Market revenue (US$ Million) by country, 2024-2031
8.3. Asia Pacific
8.3.1. Asia Pacific Hematological Malignancies Drugs Market revenue (US$ Million) By Drugs, 2024-2031
8.3.2. Asia Pacific Hematological Malignancies Drugs Market revenue (US$ Million) By Pipeline Products, 2024-2031
8.3.3. Asia Pacific Hematological Malignancies Drugs Market revenue (US$ Million) By Indications, 2024-2031
8.3.4. Asia Pacific Hematological Malignancies Drugs Market revenue (US$ Million) by country, 2024-2031
8.4. Latin America
8.4.1. Latin America Hematological Malignancies Drugs Market revenue (US$ Million) By Drugs, 2024-2031
8.4.2. Latin America Hematological Malignancies Drugs Market revenue (US$ Million) By Pipeline Products, 2024-2031
8.4.3. Latin America Hematological Malignancies Drugs Market revenue (US$ Million) By Indications, 2024-2031
8.4.4. Latin America Hematological Malignancies Drugs Market revenue (US$ Million) by country, 2024-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa Hematological Malignancies Drugs Market revenue (US$ Million) By Drugs, 2024-2031
8.5.2. Middle East & Africa Hematological Malignancies Drugs Market revenue (US$ Million) By Pipeline Products, 2024-2031
8.5.3. Middle East & Africa Hematological Malignancies Drugs Market revenue (US$ Million) By Indications, 2024-2031
8.5.4. Middle East & Africa Hematological Malignancies Drugs Market revenue (US$ Million) by country, 2024-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. AbbVie Inc.
9.2.2. Amgen Inc.
9.2.3. Bristol-Myers Squibb Company
9.2.4. F. Hoffmann-La Roche Ltd.
9.2.5. Gilead Sciences, Inc.
9.2.6. GlaxoSmithKline plc
9.2.7. Immune-Onc Therapeutics, Inc.
9.2.8. Johnson & Johnson Services, Inc.
9.2.9. Merck & Co., Inc.
9.2.10. Novartis International AG
9.2.11. Pfizer Inc.
9.2.12. Sanofi S.A.
9.2.13. Takeda Pharmaceutical Company Limited
9.2.14. Other Prominent Players
Global Hematological Malignancies Drugs Market , by Drugs
Global Hematological Malignancies Drugs Market , by Pipeline Products
Global Hematological Malignancies Drugs Market , by Indications
Global Hematological Malignancies Drugs Market , by Region
North AmericaHematological Malignancies Drugs Market , by Country
Europe Hematological Malignancies Drugs Market , by Country
Asia PacificHematological Malignancies Drugs Market , by Country
Latin America Hematological Malignancies Drugs Market , by Country
Middle East & Africa Hematological Malignancies Drugs Market , by Country
Competitive Landscape
Other Prominent Players
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
